by Michelle N. Bremer  , Garrick J. Gama  , Omkar Rao  , Eugene Golts  , Deepa Kurup  , Aarya Kafi  , Christine M. Lin  , Gordon Yung  and Kamyar Afshar

Received: 28 November 2022;  Published: 10 April 2023;  doi: 10.21926/obm.transplant.2302180

Race, while a social construct, has a strong effect on a person’s health. There is limited data on racial disparities within lung transplantation (LTx), especially for Hispanic recipients. Therefore, the aim of this study was to identify inequalities that may involve this population. We analyzed historical data from the Organ Procurement and Transplantation Network (OPTN) and performed a retrospective review of Hispanic and Caucasian patients who underwent lung transplantation in the United States between May [...]

by Suresh Keshavamurthy  and Cody Russell

Received: 11 January 2023;  Published: 04 April 2023;  doi: 10.21926/obm.transplant.2302179

A boundless spectrum of chronic lung diseases is said to effect over 500 million persons globally. Lung transplantation is a well-established therapeutic option for patients suffering from end-stage lung diseases, however waitlist mortality and primary graft failure remain major determinants as post-transplantation 5-year survival is just above 50 percent. Recent innovations in lung transplantation have been aimed at increasing organ availability, improving allograft quality, function, and longevity. Ex-vivo Lung P [...]

by Leona A. Holmberg  , Michael Linenberger  and Laura Connelly-Smith

Received: 06 May 2022;  Published: 30 March 2023;  doi: 10.21926/obm.transplant.2301178

RICE is salvage therapy for treating CD20+non-Hodgkin lymphoma (NHL). It is combined with G-CSF to collect autologous peripheral blood stem cells (aPBSC). Little data exists, though, on the combination of G-CSF and Plerixafor after RICE in mobilizing adequate number of CD34 cells and the product’s immune content. We report on the results of twenty CD20+ NHL patients after RICE, G-CSF and Plerixafor were given to collect aPBSC. The median number of cells collected was 12.92 × 106 CD34 cells/kg (range 5.4 [...]

by Kamyar Afshar  , Michelle N Bremer  , Deepa Kurup  , Michael Bernales  , Elizabeth Schonhoft  , Luis Santana  , Caro Davila  , Gina Schooler  , Gordon Yung  , Travis Pollema  and Eugene Golts

Received: 07 November 2022;  Published: 14 March 2023;  doi: 10.21926/obm.transplant.2301177

Lung transplant (LTx) survival and quality of life have been steadily improving, partially from changes in candidate selection for transplantation. There are well-known high-risk factors that lead to poor LTx outcomes, which may be referred to as ‘accounted’ risks. However, there are also other ‘unaccounted’ risks that are not included in the existing model for expected LTx survival to help programs for resource allocation. We performed a retrospective cohort study of all LTx recipients over the age of 18 at UC San [...]

by Deepika Razia  , Ashraf Omar  , Katherine Grief  , Rajat Walia  and Sofya Tokman

Received: 20 November 2022;  Published: 01 March 2023;  doi: 10.21926/obm.transplant.2301176

Careful selection of lung transplant (LT) recipients with cystic fibrosis (CF) may improve outcomes; therefore, we studied the impact of sex and age at the time of LT on long-term survival of patients with CF. LT recipients with CF who received post-LT care at our center between July 1, 2007 and April 30, 2021 were included. The primary outcome was death or retransplantation. Cox proportional hazard analysis and the Kaplan-Meier method were used. Of 59 included LT recipients, the median age at first LT was 28 (22, [...]

by Alfonso H. Santos  , Amer Belal  , Hisham Ibrahim  and Muhannad A. Leghrouz

Received: 19 August 2022;  Published: 21 February 2023;  doi: 10.21926/obm.transplant.2301175

We aimed to identify the non-renal risk factors for simultaneous liver-kidney transplantation (SLKT) vs. liver transplantation alone (LTA) in end-stage liver disease (ESLD) patients with estimated glomerular filtration rate (eGFR) <60 ml/min, not on dialysis. Using organ procurement and transplantation network data, we studied adult ESLD patients who received deceased-donor SLKT or LTA in July 2002-Mar 2016 with a 4-point modification of renal disease (MDRD) equation-estimated glomerular filtration rate (eGFR) s [...]

by Michelle F. Sener  , Thaddeus Rogozinski  , James S. George  , Deepak Mital  and Douglas P. Slakey

Received: 08 November 2022;  Published: 29 January 2023;  doi: 10.21926/obm.transplant.2301174

Cytomegalovirus (CMV) infection is the most common infection affecting kidney transplant recipients [1]. CMV may be present as asymptomatic viremia or with symptoms ranging from mild to significant tissue-invasive disease [1,2,3]. Optimal kidney graft function and survival requires that transplant care teams carefully assess individual patient risk of CMV [2,3]. Appropriate patient surveillance and prophylaxis are essential to ensure the best long-term kidney transplant results. Effective treatment of CMV disease r [...]

by Ashwini Arjuna  , Deepika Razia  , Devika Sindu  , Michael T. Olson  , Lara Schaheen  , Ross M. Bremner  , Rajat Walia  and Kendra McAnally

Received: 25 October 2022;  Published: 06 January 2023;  doi: 10.21926/obm.transplant.2301173

Few reports have described successful lung transplantation from a donor with a history of SARS-CoV-2 infection, and outcomes beyond 3 to 6 months remain unknown. After weighing the urgency and life-saving benefits of lung transplantation against the risk of viral transmission, we successfully performed a bilateral lung transplant from a donor with confirmed SARS-CoV-2 infection with mild symptoms 2 months before donation. At 1 year after transplant, there is no evidence of donor-derived viral transmission, and allo [...]

by OBM Transplantation Editorial Office

Received: 04 January 2023;  Published: 04 January 2023;  doi: 10.21926/obm.transplant.2301172

The editors of OBM Transplantation would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2022. We greatly appreciate the contribution of expert reviewers, which is crucial to the journal’s editorial process. We aim to recognize reviewer contributions through several mechanisms, of which the annual publication of reviewer names is one. Reviewers receive a voucher entitling them to a discount on their next LIDSEN publication and can download a certificate of recog [...]

by Braulio A. Marfil-Garza  and Tatsuya Kin

Received: 11 December 2022;  Published: 19 December 2022;  doi: 10.21926/obm.transplant.2204171